NCT01304095.

Methods	Study design: parallel‐group trial Duration of follow‐up: 6 months Method of randomisation: not described Method of concealment of allocation: not described Blinding: open‐label Power calculation: not mentioned Phases of the study: 1 (treatment phase)
Participants	Total number: 160 (estimated) Country of enrolment: USA Setting/location: not specified Diagnostic criteria (stable angina pectoris): symptoms of angina with evidence of stable CAD (macrovascular angina) Comorbidities: metabolic syndrome Inclusion criteria: Evidence of stable Coronary Artery Disease MI > 30 days prior to enrolment PCI > 30 days prior to enrolment CABG > 30 days prior to enrolment Angiography showing > 50% stenosis in a major vessel, branch or bypass graft > 30 days prior to enrolment Metabolic Syndrome as evidenced by at least one of the following risk factors: Abdominal Obesity (elevated waist circumference) Men ‐ waist circumference ≥ 40 inches (102 cm) Asians/Asian Americans ≥ 35.5 inches (90 cm) Women ‐ waist circumference ≥ 35 inches (88 cm) Asians/Asian Americans ≥ 31.5 inches (80 cm) Atherogenic dyslipidaemia (either one or both) Triglycerides ≥ 150 mg/dL Reduced HDL Men ‐ HDL ≤ 40 mg/dL Women ‐ HDL ≤ 50 mg/dL Elevated Blood Pressure (equal to or greater than 130/85) Elevated fasting glucose (equal to or greater than 100 mg/dL)
Interventions	Number of intervention groups: 2 Concomitant medications: standard medical therapy Excluded medications: those mentioned in exclusion criteria Control group Intervention: no treatment Duration of intervention: 6 months Ranolazine group Intervention: ranolazine (type of formulation not specified) 500/1000 mg twice daily Duration of intervention: 6 months
Outcomes	Total number of outcomes: 6 (ETT parameters, fasting glucose, angina (SAQ scale), concomitant medications, lipid profile, HbA1c) OUTCOMES No outcome meets inclusion criteria
Notes